0.3813

2.50% 0.0093

After Hours: .39 0.0087 +2.28%

Cytosorbents Corp (CTSO)

Overview News Price History Option Chain Financials Why CTSO Down? Discussions Forecast Stock Split

Cytosorbents Corp stock is traded at $0.3813, with a volume of 42,383. It is up +2.50% in the last 24 hours and down -7.23% over the past month. CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.

Previous Close:

$0.372

Open:

$0.3693

24h Volume:

42,383

Relative Volume:

0.28

Market Cap:

$23.96M

Revenue:

$37.20M

Net Income/Loss:

$-11.85M

P/E Ratio:

-1.9984

EPS:

-0.1908

Net Cash Flow:

$-10.59M

1W Performance:

-2.23%

1M Performance:

-7.23%

6M Performance:

-43.17%

1Y Performance:

-66.55%

1-Day Range:

$0.3693

$0.40

1-Week Range:

$0.3693

$0.4601

52-Week Range:

$0.3504

$1.22

Cytosorbents Corp Stock (CTSO) Company Profile

Name

Cytosorbents Corp

Sector

Healthcare (1096)

Industry

Medical Devices (140)

Phone

973-329-8885

Address

305 COLLEGE ROAD EAST, PRINCETON, NJ

Employee

129

Twitter

@CytoSorbents

Next Earnings Date

2026-08-06

Latest SEC Filings

CTSO's Discussions on Twitter

Compare CTSO vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTSO Cytosorbents Corp	0.3813	23.96M	37.20M	-11.85M	-10.59M	-0.1908
ABT Abbott Laboratories	93.93	163.61B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	329.78	126.42B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	83.87	107.36B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	44.77	66.54B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	92.21	53.09B	6.30B	1.07B	1.09B	1.8406

Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-07-23	Initiated	B. Riley Securities	Buy
Oct-14-21	Resumed	B. Riley Securities	Buy
Sep-17-20	Initiated	Jefferies	Buy
Sep-01-20	Initiated	SVB Leerink	Outperform
Aug-08-17	Reiterated	Maxim Group	Buy
Oct-26-16	Initiated	Aegis Capital	Buy
May-24-16	Initiated	Maxim Group	Buy
Oct-29-15	Upgrade	WBB Securities	Speculative Buy → Buy
May-12-15	Reiterated	MLV & Co	Buy
Apr-01-15	Reiterated	MLV & Co	Buy
Mar-05-15	Initiated	MLV & Co	Buy
Feb-25-15	Initiated	WBB Securities	Speculative Buy
Jan-27-15	Reiterated	H.C. Wainwright	Buy

View All

Cytosorbents Corp Stock (CTSO) Latest News

Jul 06, 2026

CytoSorbents Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Jul 06, 2026

CytoSorbents (NASDAQ: CTSO) falls below Nasdaq $35M value test, faces 180-day cure - Stock Titan

Jul 06, 2026

Jun 27, 2026

CTSO | Cytosorbents Corp. Executive Compensation - Quiver Quantitative

Jun 27, 2026

Jun 25, 2026

[ARS] Cytosorbents Corp SEC Filing - Stock Titan

Jun 25, 2026

CytoSorbents (NASDAQ: CTSO) seeks reverse split to support Nasdaq listing - Stock Titan

Jun 25, 2026

CytoSorbents (NASDAQ: CTSO) Targets Major ICU & Cardiac Surgery Markets With Breakthrough Blood Purification Tech, Eyes 2026 Cash Flow Breakeven and FDA Approval 246 - Minichart

Jun 25, 2026

CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs - TradingView

Jun 25, 2026

CytoSorbents (NASDAQ: CTSO) details DrugSorb-ATR FDA meetings, sales and cash flow goals - Stock Titan

Jun 25, 2026

Jun 23, 2026